• Biomea Fusion scheduled Phase I results for BMF-650, an oral small-molecule GLP-1 receptor agonist, for Oct. 13, 2026.
• Data will be presented in a conference call and webcast, signaling a near-term readout for its diabetes and obesity pipeline.
• No trial outcomes were disclosed in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121630PRIMZONEFULLFEED9844177) on October 12, 2026, and is solely responsible for the information contained therein.